Ideas to action: independent research for global prosperity
Research
Innovative, independent, peer-reviewed. Explore the latest economic research and policy proposals from CGD’s global development experts.
WORKING PAPERS
April 11, 2024
POLICY PAPERS
April 15, 2024
CGD NOTES
April 08, 2024
WORKING PAPERS
April 04, 2024
All Research
Filters:
Experts
Facet Toggle
Topics
Facet Toggle
Publication Type
Facet Toggle
Time Frame
Facet Toggle
Research
POLICY PAPERS
October 04, 2022
Global reserves can serve as a global public good, facilitating the short-term global recovery from the economic impacts of the pandemic and Russian invasion of Ukraine, as well as the longer-term global transition to a sustainable and equitable economic future. Strategic allocation of Special Drawi...
CGD NOTES
August 31, 2022
When the G20 pledges of $100 billion of SDR recycling materialize, there will no doubt be much self-congratulatory celebration. But the celebrations will be meaningless if the SDRs do not make their way to the low- and middle-income countries (LMICs) that need them. Will we be able to tell if the SD...
WORKING PAPERS
August 08, 2022
Low tax compliance in low- and middle-income countries around the world limits the ability of governments to offer effective public services. This paper reports the results of a randomly rolled out text message campaign aimed at promoting tax compliance among landowners in Dar es Salaam, Tanzania. L...
REPORTS
May 12, 2022
To hear talk of it, you might think educating girls is a silver bullet to solve all the world’s ills. A large and still growing collection of research demonstrates the wide-ranging benefits of girls’ education. Recent research has nuanced some of those findings, but the fundamental result stands: Ed...
BRIEFS
April 28, 2022
COVID-19 has disrupted health systems across the globe. Nigeria reported its first COVID-19 case in February 2020, and, since then, the government has rolled out four vaccines to help control the pandemic—Moderna, Oxford-Astra Zeneca (AZ), Johnson & Johnson (J&J) and Pfizer-BioNTech.